Anderson Hoagland & CO Regeneron Pharmaceuticals, Inc. Transaction History

Anderson Hoagland & CO

$894 Million
Q1 2024

A detailed history of Anderson Hoagland & CO transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Anderson Hoagland & CO holds 3,489 shares of REGN stock, worth $3.64 Million. This represents 0.38% of its overall portfolio holdings.

Number of Shares

3,489

Previous 5,055 30.98%

Holding current value

$3.64 Million

Previous $4.44 Million 24.35%

% of portfolio

0.38%

Previous 0.54%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 11, 2024	SELL	$902.69 - $993.35 $1.41 Million - $1.56 Million	-1,566 Reduced 30.98%	3,489 $3.36 Million
Q4 2023 Jan 17, 2024	SELL	$775.18 - $881.7 $42,634 - $48,493	-55 Reduced 1.08%	5,055 $4.44 Million
Q3 2023 Oct 10, 2023	BUY	$692.45 - $844.37 $1,384 - $1,688	2 Added 0.04%	5,110 $4.21 Million
Q4 2022 Jan 20, 2023	BUY	$705.89 - $766.39 $415,063 - $450,637	588 Added 13.01%	5,108 $0
Q3 2022 Oct 11, 2022	BUY	$573.97 - $724.32 $9,183 - $11,589	16 Added 0.36%	4,520 $3.11 Million

Q4 2021 Jan 25, 2022	BUY	$543.48 - $670.97 $48,369 - $59,716	89 Added 2.02%	4,504 $2.8 Million
Q3 2021 Oct 07, 2021	BUY	$574.03 - $680.96 $2.53 Million - $3.01 Million	4,415 New	4,415 $2.67 Million
Q1 2021 Apr 09, 2021	SELL	$446.73 - $548.2 $1.17 Million - $1.44 Million	-2,624 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$478.3 - $607.98 $513,694 - $652,970	1,074 Added 69.29%	2,624 $1.27 Million
Q3 2020 Oct 06, 2020	SELL	$544.75 - $658.21 $27,237 - $32,910	-50 Reduced 3.13%	1,550 $967,000
Q2 2020 Jul 06, 2020	BUY	$493.32 - $643.92 $789,312 - $1.03 Million	1,600 New	1,600 $998,000

Others Institutions Holding REGN

# of Institutions

1,426

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $112B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Anderson Hoagland & CO, based on Form 13F filings with the SEC.

News

Stay updated on Anderson Hoagland & CO with notifications on news.

Account

Anderson Hoagland & CO Regeneron Pharmaceuticals, Inc. Transaction History